Background-Colitis associated dysplasia
and cancer often have deletions involving the long arm of chromosome 18q, suggesting the location of a tumour suppressor gene critical for their tumorigenesis. The DPC4 gene, which is genetically inactivated in pancreatic and other cancers, has recently been described. Aim-Because DPC4 is located at 18q2l-1, the hypothesis that it could be a mutated tumour suppressor gene in colitis associated neoplasms was tested. Patients-Advanced neoplastic lesions from six patients having chronic colitis were analysed for DPC4. Methods-Individual exons of DPC4 were amplified by the polymerase chain reaction (PCR) and sequenced from genomic DNA of tissue specimens dissected by cryostat.
Results-DPC4 was found to have biallelic inactivation in one of three neoplasms shown to have allelic loss of 18q. The mutation had been acquired somatically in a plaque of high grade dysplasia. The mutation created a non-sense codon, which would cause premature termination of ND=not determined. *K-ras, p53, and DPC4 mutations are given by codon and the predicted translation product using the single letter amino acid code. fs del=frameshift deletion mutation; fs ins=frameshift insertion; splice=splice acceptor site mutation. For APC, mutations were identified by a screening assay for mutations producing truncated products, and the failure to identify a mutation does not exclude the possibility of other types of mutations. For DPC4, the presence of homozygous deletions is not excluded. CC-4 had two mutations in APC. CC-6a had a p53 mis-sense mutation on each allele.
tFAL=fractional allelic loss. Mutations of DPC4 status from the current study is shown in a genetic context with data from previous publications.'
Hoque, Hahn, Schutte, Kern of DPC4, at 18q21 -near the DCC gene, is known to be commonly involved in loss of heterozygosity events in colitis associated neoplasms. The deletions of chromosome 18, however, often involve very large regions, and it has been difficult to identify the gene(s) which may serve as the genetic target of these events. Here, we report a DPC4 point mutation in one of three advanced colitis associated neoplasms which harboured allelic loss of 1 8q. This is the first gene target on 18q to be pinpointed by the identification of a point mutation in colitis associated dysplasia. Interestingly, the mutation was found in the non-invasive dysplastic plaque, rather than the carcinomas. Follow up efforts would benefit from a larger series, which should include an assessment of prognostic importance for lesions having DPC4 inactivation. 
